marketinsider

Breaking Barriers: Stockholm’s Vice Mayor Takes a Stand Against Far-Right Intolerance…in Drag!

Stockholm’s deputy mayor glam up in drag for children’s story hour Jan Jonsson promotes tolerance and inclusivity Stockholm’s deputy mayor donned red lipstick and bouffant hair as he glammed up in drag for a children’s story hour, part of a campaign against “intolerance and populism” launched this week. Jan Jonsson, a 45-year-old member of the…

Read More

Uncovering the Truth: Why the Catholic Church Refused to Say Final Prayers for Hon. Paul Kato Lubwama

Unveiling the Reasons: Understanding Why the Catholic Church Denied Final Prayers for Hon Paul Kato Lubwama Shocking Revelation News has emerged surrounding the Catholic Church’s refusal to preside over prayers for the late Hon Paul Kato Lubwama, which has caused shock and disappointment among believers and raised questions about the Church’s adherence to its own…

Read More

Get Ready to Cash In: Greystone Housing Impact Investors LP Announces Quarterly Distribution and Bonus Bucks!

Greystone Housing Impact Investors LP Announces Regular Quarterly Cash Distribution and Supplemental BUCs Distribution OMAHA, Neb., June 14, 2023 (GLOBE NEWSWIRE) On June 14, 2023, Greystone Housing Impact Investors LP (NYSE: GHI) (the “Partnership”) announced that the Board of Managers of Greystone AF Manager LLC (“Greystone Manager”) declared a distribution to the Partnership’s Beneficial Unit…

Read More

Breaking News: Cigniti Technologies Takes Home Bronze Stevie and People’s Choice Stevie Award at 2023 American Business Awards!

Delighting in the Success of iNStaTM: A Stevie® Award Winner! Celebrating Cigniti’s AI-Powered Scriptless Test Automation Platform Have you heard the buzz? iNStaTM, Cigniti’s innovative AI-powered Scriptless Test Automation Platform, has recently been awarded the Bronze Stevie® Award in the Low Code/No Code Platform category. But that’s not all – it also clinched the People’s…

Read More

Breaking News: Ventyx Biosciences Begins Phase 1 Trial for VTX3232, a Revolutionary CNS-Penetrant NLRP3 Inhibitor

Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232 Topline Data Expected in H1 2024 ENCINITAS, Calif., June 14, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) Ventyx Biosciences, a clinical-stage biopharmaceutical company, has recently announced the initiation of dosing in a Phase 1 trial of VTX3232. This novel oral…

Read More